A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Among pediatric patients with cerebral venous thrombosis, treatment with rivaroxaban or standard anticoagulants resulted in a similarly reduced risk for recurrent VTE or bleeding.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
Study results confirmed that dabigatran has comparable efficacy and safety as standard of care heparin or vitamin K antagonists for acute VTE in children.
A novel diagnostic algorithm was able to safely rule out DVT in patients visiting an emergency department, thereby reducing the need for ultrasound imaging.
A retrospective analysis showed similar outcomes for cyclophosphamide as seen with rituximab in treatment of immune thrombotic thrombocytopenic purpura.
A retrospective analysis shows that real-world outcomes with caplacizumab for thrombotic thrombocytopenic purpura are similar to clinical trial results.
Caplacizumab with therapeutic plasma exchange and immunosuppression appears to prevent unfavorable clinical outcomes in patients with immune-mediated TTP.
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
A single-center study in Canada found a point prevalence of Gaucher disease of 0.5% among Canadian patients referred to a hematologist for thrombocytopenia.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
A team of researchers evaluated the current health system-wide practices and protocols associated with the administration of DOACs in anticoagulation clinics.
A DOAC population-based management tool may help determine and address potential interactions between DOACs and NSAIDs in patients receiving both treatments.
Patients with sickle cell disease may have an increased risk for venous thromboembolic events, especially pulmonary embolism, following surgical splenectomy.
Researchers reported a safe and effective treatment strategy to prevent clot progression in neonates and children with catheter-related arterial thrombosis.
Thrombotic thrombocytopenic purpura (TTP) related to systemic lupus erythematosus may not cause worse outcomes compared with primary immune-mediated TTP.
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
In patients hospitalized with COVID-19, thrombi in segmental pulmonary arteries are common and are located in opacitated lung segments, which may suggest local clot formation.
A position paper recently published by the National Pulmonary Embolism Response Team outlines an approach for diagnosing and treating pulmonary embolism in patients with COVID-19.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
As PKD directly affects the catalysis of substrates and products involved in the production of ATP, the glycolytic pathway is compromised, thus leading to several cellular defects.
